ISSN: 2469-9837
Peter Revill
Biomarkers play a task in understanding and diagnosing disease and in indicating how patients answer treatment. If they’re appropriately applied, biomarkers can enhance the productivity of pharmaceutical R&D and play a key role in regulatory processes. The challenge is to seek out the relevant markers from the gamut of biomarker reports, and to attach experimental biomarker research with drug development and clinical utility. We have developed a totally indexed biomarker database using standardized terminology applied to original reference sources including patents, scientific journals and conference abstracts. Here I demonstrate the facility of employing a standardized indexing system to travel beyond article retrieval; identifying biomarkers that would potentially function drug development tools for target validation in MS research. I also illustrate how an equivalent approach are often wont to identifying potential new drug targets for MS. If they’re appropriately applied, biomarkers can enhance the productivity of pharmaceutical R&D and play a key role in regulatory processes. The challenge is to seek out the relevant markers from the gamut of biomarker reports, and to attach experimental biomarker research with drug development and clinical utility.